<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01970748</url>
  </required_header>
  <id_info>
    <org_study_id>V101C-016ï¼›V102C-094</org_study_id>
    <nct_id>NCT01970748</nct_id>
  </id_info>
  <brief_title>Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices</brief_title>
  <acronym>P-HCC</acronym>
  <official_title>Endoscopic Treatment Versus Propranolol for Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized comparison within the endoscopic esophageal varices ligation versus non-selective&#xD;
      beta-blocker in the primary prevention of esophageal variceal bleeding in patients with HCC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastroesophageal variceal bleeding is a major complication of cirrhosis and has high rate of&#xD;
      rebleeding and mortality. In these 20 to 30 years, medical advances have significantly&#xD;
      improved the prognosis of variceal bleeding. Nevertheless, the mortality of gastroesophageal&#xD;
      variceal bleeding is still nearly 20 to 30%.&#xD;
&#xD;
      Hepatocellular carcinoma (HCC) is one of the most common malignancy in Asian, and is also the&#xD;
      special group in portal hypertension. Studies in Italy, more than 50% of patients diagnosed&#xD;
      with HCC are concomitant with esophageal varices. HCC and portal thrombosis caused by HCC&#xD;
      itself are all independent risk factors of gastroesophageal bleeding. Once the bleeding,&#xD;
      rebleeding rate is up to 50% even if early use of vasoconstrictor agents and endoscopic&#xD;
      therapy, which is generally 2 times in patients with cirrhosis.&#xD;
&#xD;
      According to 2010 Baveno V recommendations, non-selective beta-blockers (NSBB) or endoscopic&#xD;
      variceal ligation (EVL) are first choice for primary prevention of first variceal bleeding in&#xD;
      cirrhotic patients. However, risk factors of variceal bleeding caused by HCC or cirrhosis are&#xD;
      different, and portal hypertension is particularly high in patients with HCC and may be&#xD;
      combined with portal vein thrombosis. NSBB sufficient to decreased portal hypertension to&#xD;
      prevent variceal bleeding is not clear. In Hepatology 2010, Lebrec claimed that NSBB used for&#xD;
      cirrhotic patients with refractory ascites had poor prognosis, the main cause of death were&#xD;
      the progression of HCC and sepsis, although the impact of NSBB for HCC patients are not&#xD;
      entirely clear, but this issue remind clinicians to careful use of NSBB in these patients.&#xD;
      Since NSBB possible adverse effects, the use of EVL to prevent bleeding in patents with HCC&#xD;
      is superior to NSBB? These need further study to clarify. So we designed this study to&#xD;
      evaluate the feasibility and effectiveness of using EVL or NSBB to prevent first bleeding in&#xD;
      patients with HCC concomitant with esophageal varices.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 25, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bleeding Esophageal Varices</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate&gt;55 or systemic blood pressure&gt;90mmHg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esophageal variceal ligation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy. After eradication, follow-up endoscopy every 3 months and variceal ligation again if recurrence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate&gt;55 or systemic blood pressure&gt;90mmHg)</description>
    <arm_group_label>Propranolol</arm_group_label>
    <other_name>Inderal, Cardolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Esophageal variceal ligation</intervention_name>
    <description>Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy</description>
    <arm_group_label>Esophageal variceal ligation</arm_group_label>
    <other_name>EVL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between 20 and 80 years old&#xD;
&#xD;
          -  Hepatocellular carcinoma (HCC) associated with esophageal varices&#xD;
&#xD;
          -  F2 or F3 esophageal varices (Beppu et al classification)&#xD;
&#xD;
          -  Hepatocellular carcinoma (HCC) associated with portal thrombosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of esophageal variceal bleeding&#xD;
&#xD;
          -  Had received endoscopic variceal ligation (EVL) or endoscopic injection sclerotherapy&#xD;
             (EIS)&#xD;
&#xD;
          -  Pregnancy, or the patients with other terminal illness (such as other terminal&#xD;
             cancers, heart failure, renal failure...)&#xD;
&#xD;
          -  Propranolol contraindications (such as atrioventricular block, heart failure, chronic&#xD;
             obstructive pulmonary disease, asthma, poorly controlled diabetes, severe peripheral&#xD;
             arterial disease...)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Chih Hou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming-Chih Hou, MD</last_name>
    <phone>886-2-28712121</phone>
    <phone_ext>1320</phone_ext>
    <email>mchou@vghtpe.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Chih Hou, MD</last_name>
      <phone>886-2-28712121</phone>
      <phone_ext>1320</phone_ext>
      <email>mchou@vghtpe.gov.tw</email>
    </contact>
    <contact_backup>
      <last_name>Han-Chieh Lin, MD</last_name>
      <phone>886-2-28712121</phone>
      <phone_ext>7506</phone_ext>
      <email>hclin@vghtpe.gov.tw</email>
    </contact_backup>
    <investigator>
      <last_name>Ming-Chih Hou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 22, 2013</study_first_submitted>
  <study_first_submitted_qc>October 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2013</study_first_posted>
  <last_update_submitted>August 29, 2019</last_update_submitted>
  <last_update_submitted_qc>August 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Variceal bleeding</keyword>
  <keyword>Portal hypertension</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Endoscopic variceal ligation</keyword>
  <keyword>Non-selective beta-blocker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
    <mesh_term>Varicose Veins</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

